KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deferred Tax Liability (2022 - 2025)

Historic Non-Current Deferred Tax Liability for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q3 2025 value amounting to $23.3 million.

  • Recursion Pharmaceuticals' Non-Current Deferred Tax Liability rose 1377619.05% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year increase of 1377619.05%. This contributed to the annual value of $16.6 million for FY2024, which is 202.74% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Non-Current Deferred Tax Liability stood at $23.3 million for Q3 2025, which was up 1377619.05% from $23.8 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Non-Current Deferred Tax Liability high stood at $23.8 million for Q2 2025, and its period low was $168000.0 during Q3 2024.
  • Over the past 4 years, Recursion Pharmaceuticals' median Non-Current Deferred Tax Liability value was $14.3 million (recorded in 2022), while the average stood at $12.2 million.
  • In the last 5 years, Recursion Pharmaceuticals' Non-Current Deferred Tax Liability tumbled by 9129.98% in 2024 and then surged by 1377619.05% in 2025.
  • Quarter analysis of 4 years shows Recursion Pharmaceuticals' Non-Current Deferred Tax Liability stood at $11.9 million in 2022, then soared by 41.77% to $16.9 million in 2023, then dropped by 2.03% to $16.6 million in 2024, then surged by 40.65% to $23.3 million in 2025.
  • Its last three reported values are $23.3 million in Q3 2025, $23.8 million for Q2 2025, and $22.4 million during Q1 2025.